6-amino-5-chloro-3,4-dihydronaphthalen-1(2H)-one | 107757-24-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6-amino-5-chloro-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 6-amino-5-chloro-1-tetralone；6-amino-5-chloro-3,4-dihydro-2H-naphthalen-1-one
• CAS: 107757-24-4
• 化学式: C₁₀H₁₀ClNO
• mdl: MFCD18648253
• 分子量: 195.648
• InChiKey: LJLOFXULPFXQCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-amino-5-chloro-3,4-dihydronaphthalen-1(2H)-one 以90%的产率得到6-Amino-5-chloro-1-cyano-(3,4-dihydronaphthalene)
  参考文献：
  名称：

  Adrenergic amidines

  摘要：

  本公开涉及的肾上腺素类化合物由以下式表示：其中m为0、1或2；R.sub.1、R.sub.2、R.sub.3和R.sub.7取自氢、羟基、较低烷基、较低烷氧基、卤素、氨基、乙酰胺基或NHSO.sub.2 R的群，其中R取自氢或较低烷基，但要求R.sub.1、R.sub.2、R.sub.3和R.sub.7不能同时为氢或卤素，且当R.sub.1、R.sub.2、R.sub.3和R.sub.7中的一个为卤素时，其他的不能同时为氢，当R.sub.1、R.sub.2、R.sub.3和R.sub.7中有两个为卤素时，其他两个不能同时为氢，而且当R.sub.1和R.sub.7同时为甲氧基时，R.sub.2和R.sub.3为氢；R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7结合在一起可以形成甲二氧基或乙二氧基桥；或者R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7与芳香环结合在一起可以形成苯并咪唑或吲哚桥；R.sub.4和R.sub.5为氢或结合在一起形成下式的闭环：其中n为1或2，组合的实线和虚线代表单键或双键，当n为1时，R.sub.6取自氢或较低烷基，以及其药用可接受的盐。

  公开号：

  US04634705A1
• 作为产物：
  描述：

  6-氨基-1,2,3,4-四氢-1-萘酮 在 sodium chloride 作用下， 以 二甲基亚砜 为溶剂， 生成 6-amino-5-chloro-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  Understanding Flavin-Dependent Halogenase Reactivity via Substrate Activity Profiling

  摘要：

  The activity of four native FDHs and four engineered FDH variants on 93 low-molecular-weight arenes was used to generate FDH substrate activity profiles. These profiles provided insights into how substrate class, functional group substitution, electronic activation, and binding affect FDH activity and selectivity. The enzymes studied could halogenate a far greater range of substrates than have been previously recognized, but significant differences in their substrate specificity and selectivity were observed. Trends between the electronic activation of each site on a substrate and halogenation conversion at that site were established, and these data, combined with docking simulations, suggest that substrate binding can override electronic activation even on compounds differing appreciably from native substrates. These findings provide a useful framework for understanding and exploiting FDH reactivity for organic synthesis.

  DOI：

  10.1021/acscatal.6b02707

文献信息

• [EN] INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS<br/>[FR] INDAZOLES ET AZAINDAZOLES EN TANT QU'INHIBITEURS DE LRRK2
  申请人：ESCAPE BIO INC

  公开号：WO2021178780A1

  公开（公告）日：2021-09-10

  The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

  本发明涉及一种抑制LRRK2的吲唑和杂氮吲唑化合物，可用于治疗中枢神经系统疾病。
• US4634705A
  申请人：——

  公开号：US4634705A

  公开（公告）日：1987-01-06
• Adrenergic amidines
  申请人：Abbott Laboratories

  公开号：US04634705A1

  公开（公告）日：1987-01-06

  Disclosed herein are adrenergic compounds represented by the formula ##STR1## wherein m is 0, 1 or 2; R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, amino, acetamido or NHSO.sub.2 R wherein R is taken from the group consisting of hydrogen or loweralkyl, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.7 cannot simultaneously be hydrogen or halo, and provided that when one of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 is halo, the others cannot simultaneously be hydrogen and when two of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are halo, the other two cannot simultaneously be hydrogen and provided that R.sub.1 and R.sub.7 cannot simultaneously be methoxy each when R.sub.2 and R.sub.3 are hydrogen; R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together can form a methylenedioxy or ethylenedioxy bridge; or R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together with the aromatic ring can form a benzimidazole or indole bridge; and R.sub.4 and R.sub.5 are hydrogen or taken together form a closed ring of the formula ##STR2## wherein n is 1 or 2, and the combined solid and dashed line represents a single or double bond when n is 1, and R.sub.6 is taken from the group consisting of hydrogen or loweralkyl, and the pharmaceutically acceptable salts thereof.

  本公开涉及的肾上腺素类化合物由以下式表示：其中m为0、1或2；R.sub.1、R.sub.2、R.sub.3和R.sub.7取自氢、羟基、较低烷基、较低烷氧基、卤素、氨基、乙酰胺基或NHSO.sub.2 R的群，其中R取自氢或较低烷基，但要求R.sub.1、R.sub.2、R.sub.3和R.sub.7不能同时为氢或卤素，且当R.sub.1、R.sub.2、R.sub.3和R.sub.7中的一个为卤素时，其他的不能同时为氢，当R.sub.1、R.sub.2、R.sub.3和R.sub.7中有两个为卤素时，其他两个不能同时为氢，而且当R.sub.1和R.sub.7同时为甲氧基时，R.sub.2和R.sub.3为氢；R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7结合在一起可以形成甲二氧基或乙二氧基桥；或者R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7与芳香环结合在一起可以形成苯并咪唑或吲哚桥；R.sub.4和R.sub.5为氢或结合在一起形成下式的闭环：其中n为1或2，组合的实线和虚线代表单键或双键，当n为1时，R.sub.6取自氢或较低烷基，以及其药用可接受的盐。
• Understanding Flavin-Dependent Halogenase Reactivity via Substrate Activity Profiling
  作者：Mary C. Andorfer、Jonathan E. Grob、Christine E. Hajdin、Julia R. Chael、Piro Siuti、Jeremiah Lilly、Kian L. Tan、Jared C. Lewis

  DOI：10.1021/acscatal.6b02707

  日期：2017.3.3

  The activity of four native FDHs and four engineered FDH variants on 93 low-molecular-weight arenes was used to generate FDH substrate activity profiles. These profiles provided insights into how substrate class, functional group substitution, electronic activation, and binding affect FDH activity and selectivity. The enzymes studied could halogenate a far greater range of substrates than have been previously recognized, but significant differences in their substrate specificity and selectivity were observed. Trends between the electronic activation of each site on a substrate and halogenation conversion at that site were established, and these data, combined with docking simulations, suggest that substrate binding can override electronic activation even on compounds differing appreciably from native substrates. These findings provide a useful framework for understanding and exploiting FDH reactivity for organic synthesis.